With the backing of TECHLIFE CAPITAL the pharmaceutical laboratory MITEM Pharma has acquired DESFERAL, a drug of major therapeutic interest, from Novartis. This hematology drug addresses serious blood disorders, often of genetic origin (sickle cell disease, beta thalassemia).
This transforming acquisition brings the company's sales to €25 million, 75% of which are generated internationally. It was supported by Groupe Macsf and by mezzanine providers SWEN Capital Partners and Access Capital Partners.
It fully illustrates the company's development strategy, dedicated to Medicines of Major Therapeutic Interest (MITM), which TECHLIFE CAPITAL has been accompanying since 2022. These MITMs are important drugs, reference treatments and the only ones available to treat severe diseases, but for which potential supply shortages, which are on the increase, pose public health risks. MITEM Pharma's mission, in collaboration with public health authorities, patient associations and expert medical partners, is to identify these situations and to buy back, upgrade, improve or develop these major medicines in order to secure their availability, guarantee access to appropriate care and improve patients' quality of life.
TECHLIFE CAPITAL, an Article 8 SFDR Fund, is particularly committed to
accompanying this company, which has a major societal impact, in line with
its strong commitment to sustainability and ESG issues.
Further acquisitions of MITMs are planned for the coming years, as well as the development of new MITM drugs, notably in endocrinology and hematology.
#healthcare #betathalassemia #sicklecelldisease #Article8 #MITM
